


Loratadine

Cat. No.:	HY-17043		
CAS No.:	79794-75-5		
Molecular Formula:	C ₂₂ H ₂₃ ClN ₂ O ₂		
Molecular Weight:	382.88		
Target:	Histamine Receptor; Flavivirus; Dengue virus		
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (130.59 mM; Need ultrasonic)					
		Solvent	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	Concentration				
		1 mM		2.6118 mL	13.0589 mL	26.1178 mL
5 mM		0.5224 mL	2.6118 mL	5.2236 mL		
	10 mM		0.2612 mL	1.3059 mL	2.6118 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.53 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.53 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.53 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Loratadine (SCH-29851) is a selective inverse peripheral histamine H ₁ -receptor agonist with an IC ₅₀ of >32 μM. Loratadine has anti-dengue-virus (DENV) activity. Loratadine can inhibit immunologic release of inflammatory mediators.
IC₅₀ & Target	H ₁ Receptor
In Vitro	Loratadine is an antihistamine that inhibits histamine-induced activities of IL-6 and IL-8 secretion in endothelial cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- iScience. 5 January 2022, 103731.
- Eur J Pharmacol. 2023 Oct 21:176147.
- Sci Rep. 2021 Jul 22;11(1):14948.
- J Clin Psychopharmacol. 2022 Jun 2.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy. 1999 Jul;29 Suppl 3:147-50.
- [2]. Menardo JL, Horak F, Danzig MR, Czarlewski W. A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4.
- [3]. Monroe EW. Loratadine in the treatment of urticaria. Clin Ther. 1997 Mar-Apr;19(2):232-42.
- [4]. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994 Oct;48(4):617-37.
- [5]. Roman IJ, Danzig MR. Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. 1993 Spring;11(1):89-110.
- [6]. Shahan M, et al. Dengue virus causes changes of MicroRNA-genes regulatory network revealing potential targets for antiviral drugs. BMC Syst Biol. 2018 Jan 4;12(1):2.
- [7]. Kleine-Tebbe J, et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol. 1994;93(2):494-500.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA